Showing results (311-320 of 355) with videos related to

Sort By:
Pageof 36
European Journal of Haematology|July 31, 2018
Recommendations for the diagnosis and treatment of patients with polycythaemia veraAntónia Hatalova, Jiri Schwarz, Mirjana Gotic, et al.
The Lancet. Haematology|February 5, 2020
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyHeinz Gisslinger, Christoph Klade, Pencho Georgiev, et al.
Magyar Onkologia|December 10, 2024
[Diagnostic and therapeutic perspectives in RASopathies]Barnabás Péter Botos, Júlia Erhardt, Sámuel Jenei, et al.
Molecular Biology and Evolution|August 10, 2023
Interdisciplinary Analyses of Bronze Age Communities from Western Hungary Reveal Complex Population HistoriesDániel Gerber, Bea Szeifert, Orsolya Székely, et al.
Blood Advances|April 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrdan Verstovsek, Ruben Mesa, Vikas Gupta, et al.
Ejhaem|February 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosisStephen T Oh, Srdan Verstovsek, Vikas Gupta, et al.
Scientific Reports|May 13, 2025
Ancient DNA indicates 3,000 years of genetic continuity in the Northern Iranian Plateau, from the Copper Age to the Sassanid EmpireMotahareh Ala Amjadi, Yusuf Can Özdemir, Maryam Ramezani, et al.
European Journal of Haematology|October 30, 2023
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational studyAlexandre Theocharides, Heinz Gisslinger, Valerio De Stefano, et al.
Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.
Orvosi Hetilap|January 9, 2025
[Identification of genetically determined chronic childhood cytopenia in the era of molecular medicine]Bálint Egyed, Kristóf Árvai, Erik Zajta, et al.
Pageof 36